CERAMICS INTERNATIONAL
·
2022
·
IF 5.532
Feng Luo,Zhimin Li,Jiyuan Chen,Yuanshui Liu,Linzhuang Xing,Yangxi Yan,Yue Hao
Ecologically sustainable hard type piezoelectric ceramics are highly demanded for high power transducer applications in replacing lead-based piezoelectric ceramics. In this study, MnO was proposed as acceptor dopant to modify the electric properties of 0.75BiFeO 3 -0.25BaTiO 3 piezoelectric ceramics. Results showed that MnO doping reduced the lattice distortion of rhombohedral phase and facilitated the formation of pseudo cubic phase of 0.75BiFeO 3 -0.25BaTiO 3 system. Moreover, it caused the diversity of domain morphology and reduced the domain size as well. XPS analysis indicated that Mn 2+ ions suppressed the transition from Fe 3+ ions to Fe 2+ ions and gave rise to the increase of oxygen vacancies . Accordingly, the introduction of MnO synergistically increases the d 33 , K p , and Q m and lowers the tan δ of 0.75BiFeO 3 -0.25BaTiO 3 ceramics. The abnormal enhancement in hard type properties is ascribed mainly to the increase of extrinsic contribution rather than the pinning effect arising from oxygen vacancies. Finally, based on an optimal 0.75Bi(Fe 0.985 Mn 0.015 )O 3 -0.25BaTiO 3 system, an atomizer prototype was fabricated. The remarkable atomization effect suggests a competitive potential of 0.75BF-0.25BT ceramic for transducer application.
研究领域:
材料科学
·
物理学
✓ 已验证
DOI
高影响因子
INTERNATIONAL JOURNAL OF PHARMACEUTICS
·
2024
·
IF 5.3
Jieun Lee,Chang Hun Han,In Hwan Oh,Suryanarayana Allu,Hee Jin Kim,Jinsoo Kim,Woo-Sik Kim,Bum Jun Park
We present a promising method for producing amorphous drug particles using a nozzle-free ultrasonic nebulizer with polymers, specifically polyvinylpyrrolidone (PVP), poly(acrylic acid) (PAA), and Eudragit® S 100 (EUD). Model crystalline phase drugs–Empagliflozin, Furosemide , and Ilaprazole–are selected. This technique efficiently produces spherical polymer-drug composite particles and demonstrates enhanced stability against humidity and thermal conditions, compared to the drug-only amorphous particles. The composite particles exhibit improved water dissolution compared to the original crystalline drugs, indicating potential bioavailability enhancements. While there are challenges, including the need for continuous water supply for ultrasonic component cooling, dependency on the solubility of polymers and drugs in volatile organic solvents, and mildly elevated temperatures for solvent evaporation, our method offers significant advantages over traditional approaches. It provides a straightforward, flexible process adaptable to various drug-polymer combinations and consistently yields spherical amorphous solid dispersion (ASD) particles with a narrow size distribution. These attributes make our method a valuable advancement in pharmaceutical drug formulation and delivery.
研究领域:
药剂学
·
制药工程
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY
·
2015
·Vol. 30
·期 9
·1927-1934
·
IF 3.466
Lihuan Shen,Jiannan Sun,Heyong Cheng,Jinhua Liu,Zigang Xu,Jinxia Mu
For direct analyses of micro-samples and the hyphenation with nanoflow separation techniques, a low-cost demountable nanoflow nebulizer was fabricated for inductively coupled plasma mass spectrometry (ICP-MS). A small-bore capillary (20 μm) with a tapered tip served as the sample capillary of the nebulizer. The gas orifice diameter, the internal diameter and the wall thickness at the tip of the sample capillary were 160, 20, and 5 μm, respectively, which ensured stable generation of aerosol by the nebulizer at nanoflow rates down to 50 nL min−1 and an ultra-low aspiration rate (80 nL min−1). Narrower aerosol size distribution and higher analyte transport efficiency (nearly 100%) were obtained with the proposed nebulizer than with the previous demountable capillary microflow nebulizer. The sensitivity and detection limit of the proposed nebulizer at 500 nL min−1 were about one third of those obtained by using the demountable capillary microflow nebulizer at 5 μL min−1, whereas the precision of the former at 500 nL min−1 was even to some extent superior over that obtained with the latter at 5 μL min−1. Furthermore, the ICP-MS instrument could tolerate direct introduction of 100% organic solvents by using the developed nebulizer operating at nanoflow rates. It was utilized to sheathless interface nano-high performance liquid chromatography with ICP-MS for arsenic speciation analysis with good accuracy and precision, proving its strong robustness and good suitability.
研究领域:
分析化学
·
环境科学
·
仪器科学与技术
✓ 已验证
DOI
高影响因子
INTERNATIONAL JOURNAL OF PHARMACEUTICS
·
2024
·
IF 5.3
Bei Jia,Jiachen He,Ying Zhang,Wenli Dang,Bin Xing,Mengru Yang,Haonan Xie,Jiawei Li,Zhidong Liu
Chronic obstructive pulmonary disease (COPD) is a prevalent lung condition characterized by airflow obstruction, disability, and high mortality rates. Magnolol (MA), known for its anti-inflammatory and antioxidant properties, holds the potential for alleviating COPD symptoms. However, MA faces challenges like poor aqueous solubility and low bioavailability. Herein MA-loaded nanostructured lipid carriers (MA-NLC) were prepared using emulsification and solvent evaporation. These carriers exhibited a particle size of (19.67 ± 0.36) nm, a polydispersity index of (0.21 ± 0.01), and a zeta potential of (−5.18 ± 0.69) mV. The fine particle fraction of MA-NLC was (68.90 ± 0.07)%, indicating minimal lung irritation and enhanced safety. Pulmonary delivery of MA-NLC via nebulizer actively targeted the diseased lung tissues, facilitated slow release, and overcame the challenges of low oral absorption and bioavailability associated with MA. This formulation prolonged the residence time of MA and optimized its therapeutic effect in pulmonary tissues. Upon pulmonary administration, MA-NLC effectively regulated inflammatory and oxidative stress markers in COPD models, demonstrating its potential as a promising therapeutic platform for COPD management.
研究领域:
药学
·
肺科学
·
纳米技术
·
药物递送系统
✓ 已验证
DOI
PubMed
高影响因子
Pharmaceutics
·
2020
·Vol. 12
·期 1
·78
·
IF 4.421
Rui Zhang,Junhua Hu,Liangjun Deng,Sha Li,Xi Chen,Fei Liu,Shanping Wang,Khaja Shameem Mohammed Abdul,Huimin Beng,Wen Tan
Inhalation therapy with a nebulizer is widely used in chronic respiratory disease. Mixing inhalation solutions/suspensions for simultaneous inhalation is more convenient and might simplify the administration procedure. However, there are no data available to address the in vitro aerosol characteristics and physico-chemical compatibility of Combivent®(containing Salbutamol and Ipratropium bromide) with other inhalation solutions/suspensions. In order to investigate the in vitro aerosol characteristics and physico-chemical compatibility of Combivent®with Budesonide, Beclomethasone, andN-acetylcysteine, the appearance, pH, osmotic pressure, chemical stability, mass median aerodynamic diameter (MMAD), fine particles fraction (FPF), particle size corresponding to X50 (particle size, which accounts for 50% of the total cumulative percentage of volume of all particles), delivery rate, and total delivery of the mixed inhalation solution/suspension were tested. There was no change in the appearance such as a change in color or precipitation formation at room temperature. The pH, osmolality, and chemicals of the mixtures were stable for 24 h after mixing. There were no significant differences between Combivent®, Budesonide, Beclomethasone,N-acetylcysteine, and the mixtures in MMAD, FPF, X50, the delivery rate, and the total delivery. This indicates that the mixtures were physically and chemically compatible. The mixing did not influence the particle size, distribution, or delivery compatibility of the mixtures.Keywords:inhalation;nebulizer;physico-chemical;particle size and distribution;delivery compatibility;Combivent®;Budesonide;Beclomethasone;N-acetylcysteine
研究领域:
药学
·
呼吸系统疾病
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Drug Research
·
2023
·Vol. 73
·期 06
·335-340
·
IF 2.2
Guo Haihua,Zhang Rui,Deng Liangjun,Li Meng,Li Sha,Zhao Suqing
Background Inhalation preparation involves liquid or solid raw materials for delivering to lungs as aerosol or vapor. The liquid preparation for nebulizer is effective for convenient use and patient compliance and it has been extensively used in the treatment of clinical lung diseases. Clinical staff often mixes the compound ipratropium bromide with beclomethasone propionate and budesonide inhaler but reference values of inhalants for clinical use need to be established for simplifying the operation procedure. The high-performance liquid chromatography (HPLC) method of compound ipratropium bromide solution, beclomethasone propionate suspension and budesonide suspension after mixed atomization was studied. Methods The specificity, linearity, recovery (accuracy), precision and stability of compound ipratropium bromide, beclomethasone propionate and budesonide were tested to verify the developed liquid phase method. Results The developed liquid phase method had high specificity, linear R2≥0,999, recovery (accuracy) RSD (relative standard deviation) less than 2%, precision RSD less than 2,0%, and stability RSD less than 2,0%. Conclusion The liquid phase methodology developed in this study can be used for the determination of compound ipratropium bromide mixed with beclomethasone propionate and budesonide. The current methodology can also be used to provide a reference for the determination of its content after mixing, and further data support for its clinical medication.
研究领域:
药物分析
·
色谱学
·
药学
·
临床药理学
·
分析化学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）